Innoviva (INVA) Free Cash Flow Growth (5y) (2015 - 2026)
Innoviva (INVA) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
| 10 |
Innoviva |
1.69 Bn |
1.08 Bn |
75.83 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
-16.18% |
| Sep 30, 2025 |
13.64% |
| Jun 30, 2025 |
-11.19% |
| Mar 31, 2025 |
-7.93% |
| Sep 30, 2024 |
17.61% |
| Jun 30, 2024 |
-5.00% |
| Mar 31, 2024 |
-13.53% |
| Sep 30, 2023 |
12.34% |
| Jun 30, 2023 |
-5.89% |
| Mar 31, 2023 |
-12.47% |
| Sep 30, 2022 |
34.69% |
| Jun 30, 2022 |
28.40% |
| Mar 31, 2022 |
28.72% |
| Sep 30, 2021 |
67.81% |
| Jun 30, 2021 |
46.70% |
| Mar 31, 2021 |
63.27% |
| Dec 31, 2020 |
65.27% |
| Sep 30, 2020 |
94.83% |
| Jun 30, 2020 |
105.56% |
| Mar 31, 2020 |
116.25% |
